Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA in Combination With Standard Induction and Consolidation in Older AML Patients
NCT00151255Phase 3Completed
- Sponsor
- Ulm University
- Start
- Jun 2004
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tretinoin in acute myeloid leukemia (AML), sponsored by Ulm University. Primary endpoint: Event-Free Survival at 2 years. Started Jun 2004; status: completed.
02
Drugs
tretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00151255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151255.